Phase 3 Study of YERVOY Metastatic Melanoma Meets Primary Endpoint of Overall Survival
Bristol-Myers Squibb Company announced results from a second Phase 3 randomized, double blind study demonstrating...
Roche announces data to show Avastin based regimen halved the risk of disease getting...
Roche announced results from OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with...
Adaptimmune announces Opening of Phase I/II Clinical Trial in Multiple Myeloma
Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial...
First ever study to apply therapeutic approach of global immune reconstitution to treatment of...
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies...
FDA approves linagliptin tablets for the treatment of type 2 diabetes
Boehringer Ingelheim and Eli Lilly and Company announced that the U.S. Food and Drug Administration...
Gilead and MicroDose Therapeutx Announce License and Collaboration Agreement to Develop MDT-637
Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. today announced that the companies have entered...
Biogen Idec Receives Positive Opinion from the CHMP and Authorisation from Health Canada on...
Biogen Idec announced that the European Medicines Agency's Committee for Medicinal Products for Human...
Boehringer Ingelheim’s lead hepatitis C compound moves into phase III – the first within...
Boehringer Ingelheim announced the study outline for the pivotal Phase III clinical trials designed to...
Addex Initiates Phase IIa Clinical Trial of Dipraglurant-IR in Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID)
Allosteric modulation company Addex Pharmaceuticals (SIX:ADXN) announced today the initiation of a Phase IIa...
Adocia reports positive phase I clinical results on HinsBet(R), a fast-acting human insulin
Adocia, a privately-held biotechnology company specialized in regenerative medicine and in the treatment of chronic...